CAMBRIDGE, Mass. — Ironwood Pharmaceuticals, one of Cambridge’s largest biotech firms, is officially spinning off a new company Monday to treat rare diseases. And if you want a symbol of their diverging paths, look no further than the laboratory that Ironwood has used in the sleek curved building it occupies on Binney Street.

Ironwood has leased more than 200,000 square feet on the first three floors for several years, and dozens of its scientists have worked in the second-floor lab. Now it will be used by the spinoff, Cyclerion Therapeutics, which has taken over that floor. Ironwood will operate from part of the first and third floors and won’t have its own lab.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy